Identification of human antibody repertoires in curare hypersensitivity for novel diagnostics and therapies – CURAREP
NeuroMuscular Blocking Agents (NMBA; curares) relax skeletal muscles to facilitate surgeries and permit intubation, but lead to adverse reactions: (a) severe hypersensitivity reactions (anaphylaxis) thought to rely on pre-existing anti-NMBA antibodies; (b) complications due to postoperative residual curarization. Identification of patients at risk remains suboptimal due to the lack of adequate tools to detect anti-NMBA antibodies. A capturing agent exists for only one out of the four most used NMBAs, allowing reversal of profound curarization. Case reports suggested that it may also ameliorate an ongoing anaphylaxis due to that NMBA. Based on strong preliminary results, our project proposes to characterize anti-NMBA antibody repertoires in patients with various NMBA-anaphylaxis, describe activation pathways leading to anaphylaxis, develop and validate diagnostic and therapeutic molecules to ameliorate patient screening, NMBA-anaphylaxis and reverse profound neuromuscular block.
Project coordination
Pierre Bruhns (Unité Anticorps en Thérapie et Pathologie)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
ATP Unité Anticorps en Thérapie et Pathologie
INSERM-INFINITy Institut National de la Santé et de la Recherche Médicale
IDMIT Département lnfectious Disease Models and lnnovative Therapies
CHIMIE Unité de Chimie des biomolécules
AP-HP, Hopital Bichat, Service d'Auto-immunité et Hypersensibilité
UAntwerp University of Antwerpen / Department of Immunology, Allergology, Rheumatology
PARABOL DMU APHP.Nord : Périopératoire, Anesthésie, Réanimation, Ambulatoire, Blocs opératoires
Help of the ANR 706,012 euros
Beginning and duration of the scientific project:
September 2021
- 48 Months
